Notch3 regulates ferroptosis via ROS‐induced lipid peroxidation in NSCLC cells
Sign Up to like & getrecommendations! Published in 2022 at "FEBS Open Bio"
DOI: 10.1002/2211-5463.13393
Abstract: Ferroptosis is type of programmed cell death, which is known to be involved in certain cancers. Notch3 signaling is reported to be involved in the tumorigenesis of non‐small‐cell lung cancer (NSCLC) and regulates iron metabolism,… read more here.
Keywords: nsclc cells; lipid peroxidation; nsclc; regulates ferroptosis ... See more keywords
H19 promotes non‐small‐cell lung cancer (NSCLC) development through STAT3 signaling via sponging miR‐17
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cellular Physiology"
DOI: 10.1002/jcp.26530
Abstract: LncRNAs can exhibit crucial roles in the development of multiple cancers, including non‐small cell lung cancer (NSCLC). Currently, we investigated the role of lncRNA H19 in NSCLC. In our study, it was found that H19… read more here.
Keywords: nsclc; mir; lung cancer; development ... See more keywords
LncRNA DGCR5 contributes to CSC‐like properties via modulating miR‐330‐5p/CD44 in NSCLC
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cellular Physiology"
DOI: 10.1002/jcp.26590
Abstract: Non‐coding RNAs can exert significant roles various cancers, including NSCLC. Previously, we indicated that lncRNA DGCR5 can promote lung cancer progression through inhibiting hsa‐mir‐22‐3p. In our current study, we investigated the role of DGCR5 in… read more here.
Keywords: nsclc; csc like; dgcr5; cd44 ... See more keywords
Undifferentiated large cell/rhabdoid carcinoma presenting in the intestines of patients with concurrent or recent non-small cell lung cancer (NSCLC): clinicopathologic and molecular analysis of 14 cases indicates an unusual pattern of dedifferentiated metastases
Sign Up to like & getrecommendations! Published in 2021 at "Virchows Archiv"
DOI: 10.1007/s00428-021-03032-6
Abstract: Undifferentiated carcinoma metastatic to the bowel is uncommon in surgical pathology practice and might be confused with primary gastrointestinal carcinoma, melanoma, lymphoma, and others. We present 14 cases of uni- (n = 9) or multifocal… read more here.
Keywords: nsclc; carcinoma; patients concurrent; lung ... See more keywords
Second malignancy in non-small cell lung cancer (NSCLC): prevalence and overall survival (OS) in routine clinical practice
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-018-2714-5
Abstract: BackgroundPatients with non-small cell lung cancer (NSCLC) and a prior or synchronous second malignancy are generally excluded from clinical trials. Therefore, little is known on prevalence and prognosis of these patients.Methods1252 patients diagnosed with NSCLC… read more here.
Keywords: malignancy; nsclc; second malignancy; lung cancer ... See more keywords
A two-phase comprehensive NSCLC prognostic study identifies lncRNAs with significant main effect and interaction
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Genetics and Genomics"
DOI: 10.1007/s00438-022-01869-3
Abstract: Long noncoding RNA (lncRNA) are involved in regulating physiological behaviors for various malignant tumors, including non-small-cell lung cancer (NSCLC). However, few studies comprehensively evaluated both lncRNA–lncRNA interaction effects and main effects of lncRNA on overall… read more here.
Keywords: effect; validation; study; interaction ... See more keywords
The HNF1A-AS1/miR-92a-3p axis affects the radiosensitivity of non-small cell lung cancer by competitively regulating the JNK pathway.
Sign Up to like & getrecommendations! Published in 2021 at "Cell biology and toxicology"
DOI: 10.1007/s10565-021-09595-z
Abstract: BACKGROUND It has been widely reported that long non-coding RNAs (lncRNAs) could affect the varieties of tumor response to radiotherapy. LncRNA HNF1A-AS1 is transcribed from HNF1A gene cluster's antisense strand. This work focused on the… read more here.
Keywords: nsclc; as1 mir; as1; hnf1a as1 ... See more keywords
Maackia amurensis agglutinin induces apoptosis in cultured drug resistant human non-small cell lung cancer cells
Sign Up to like & getrecommendations! Published in 2019 at "Glycoconjugate Journal"
DOI: 10.1007/s10719-019-09891-1
Abstract: The emergence of multi drug resistance in non-small cell lung cancer (NSCLC) patients is a major challenge towards the efficacy of chemotherapy. Thus, there is an urgent need for the newer, better clinically targeted strategies… read more here.
Keywords: nsclc; drug; drug resistant; agglutinin ... See more keywords
A review of eligibility for patients with central nervous system (CNS) metastases from non-small cell lung cancer (NSCLC) in immunotherapy clinical trials
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Neuro-Oncology"
DOI: 10.1007/s11060-019-03219-7
Abstract: Brain metastases (BM) affect nearly half of NSCLC patients, yet these patients have historically been excluded from clinical trials due to decreased life expectancy and unclear evidence of blood brain barrier (BBB) penetration of novel… read more here.
Keywords: nsclc; disease; oncology; brain ... See more keywords
Alectinib: A Review in Advanced, ALK-Positive NSCLC
Sign Up to like & getrecommendations! Published in 2018 at "Drugs"
DOI: 10.1007/s40265-018-0952-0
Abstract: Alectinib (Alecensa®) is a potent and highly selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor. Oral alectinib monotherapy is approved in the EU as first-line treatment for adults with advanced ALK-positive non-small cell lung cancer… read more here.
Keywords: positive nsclc; nsclc; advanced alk; treatment ... See more keywords
Nanoparticles for co-delivery of Osimertinib and Selumetinib to Overcome Osimertinib-acquired Resistance in Non-small Cell Lung Cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Acta biomaterialia"
DOI: 10.1016/j.actbio.2021.05.018
Abstract: Osimertinib (OSI) is the first FDA-approved third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It can be used for treating non-small cell lung cancer (NSCLC) patients with activating EGFR mutation and for patients… read more here.
Keywords: nsclc; acquired resistance; resistance; osimertinib ... See more keywords